We are grateful to Johnson & Johnson Innovation for funding this vital work and are honored to advance medicine for our veterans and military community. This grant will provide Immunophotonics with the opportunity to expand the use of IP-001 into a previously untested combination with chemotherapy as a means of inducing systemic anti-tumor immune responses,...
Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO). Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as...
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...
Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug candidate, IP-001. The latest financing tranche, which was raised through the sale of the company’s authorized Series B Preferred Stock, has yielded $21.4 million in investments. Read More
